Pfizer (PFE) Q3 2026: EPS rebounds and full-year outlook raised
FROM THE WIRE · FINANCE.YAHOO.COM
Pfizer just put Q3 2026 on the table and the first instinctive verdict from traders was a modest nod, with the stock up about 2.6% to roughly $30.80 after the release. Headlines are all about a clean return to profitability, with basic earnings per share at $0.57 on revenue of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA return to profitability and a raised full-year outlook can support the shares of a large pharma group.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The stock rose about 2.6% to roughly $30.80 after the release.
- 02Basic earnings per share were $0.57 on revenue of $16.6 billion.
- 03Q3 2026 included an adjusted earnings beat.
- 04The full-year earnings outlook was raised.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets